SSH1 and hepatocellular carcinoma: Our data showing that the molecular inhibition or pharmacological targeting of SSH1 suppressed the viability, oncogenicity, and cancer stemness of HCC cells (Figure 3), is also of clinical relevance, and in line with similar findings in colorectal cancer, wherein the shRNA-mediated loss of SSH1 significantly impaired the migration, invasion, and colony formation of colorectal cells, in vitro [28].